Abstract
Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I / B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N-(phenylalkyl)-N- (phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate.
Keywords: class, class III antiarrhythmics, dual mode of action, n-(phenylalkyl)-n-(phenoxyalkyl)amines, gykI 16638
Current Medicinal Chemistry
Title: Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action
Volume: 11 Issue: 1
Author(s): Peter Matyus, Ildiko Varga, Tivadar Rettegi, Antal Simay, Nikolett Kallay, Laszlo Karolyhazy, Akos Kocsis, Andras Varro, Istvan Penzes and Julius Gy. Papp
Affiliation:
Keywords: class, class III antiarrhythmics, dual mode of action, n-(phenylalkyl)-n-(phenoxyalkyl)amines, gykI 16638
Abstract: Cardiac arrhythmias represent a major area of cardiovascular research, and for drug therapy, a large choice of antiarrhythmic agents have been available. However, clinical trials with antiarrhythmic drugs have recently indicated that serious side effects may considerably limit the use of various antiarrhythmic agents, in particular, for preventing arrhythmia-related mortality. Amiodarone with its complex mode of action, while exerting a strong and favorable antiarrhythmic action, posseses extracardiac untoward side effects originating from its chemical structure. In this paper, we report on our attempt to develop conceptually new, therapeutically valuable antiarrhythmic compounds, in which Class I / B and Class III features were combined into single molecules bearing no structural resemblance to amiodarone. Synthesis and pharmacological screening of series of N-(phenylalkyl)-N- (phenoxyalkyl)amines led us to discover some new promising compounds with the required dual mode of action. GYKI-16638, selected for further investigation, was also found to possess a remarkable in vivo antiarrhythmic effect, and it is now considered as a safe new antiarrhythmic drug candidate.
Export Options
About this article
Cite this article as:
Matyus Peter, Varga Ildiko, Rettegi Tivadar, Simay Antal, Kallay Nikolett, Karolyhazy Laszlo, Kocsis Akos, Varro Andras, Penzes Istvan and Papp Gy. Julius, Novel Antiarrhythmic Compounds with Combined Class IB and Class III Mode of Action, Current Medicinal Chemistry 2004; 11 (1) . https://dx.doi.org/10.2174/0929867043456232
DOI https://dx.doi.org/10.2174/0929867043456232 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?
Current Cardiology Reviews Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Cardiovascular Effects of Omega-3 Free Fatty Acids.
Current Vascular Pharmacology From Rapid to Delayed and Remote Postconditioning: The Evolving Concept of Ischemic Postconditioning in Brain Ischemia
Current Drug Targets Physiological Pacing - Quo Vadis?
Current Cardiology Reviews COVID-19 in Children: A Narrative Review
Current Pediatric Reviews Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Interventional Cardiologist Approach to Cardiac Arrest
Current Cardiology Reviews Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Uncontrolled Hypertension and Oncology: Clinical Tips
Current Vascular Pharmacology Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews Cardiac Sarcolemmal Ion Channels and Transporters as Possible Targets for Antiarrhythmic and Positive Inotropic Drugs: Strategies of the Past-Perspectives of the Future
Current Pharmaceutical Design Tuning hERG Out: Antitarget QSAR Models for Drug Development
Current Topics in Medicinal Chemistry Editorial[Hot Topic:Stem Cell Therapy for Cardiovascular Diseases:Are We Still at the Beginning of A Long Road?(Guest Editor:Lino M Goncalves)
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Risk Calculators and their Applicability to South Asians
Current Diabetes Reviews Pearls from the First Gulf Cardiac Amyloidosis Summit 2021
New Emirates Medical Journal Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry BK Channel Modulators: A Comprehensive Overview
Current Medicinal Chemistry